Information: NIBIO Achievement May. 14, 2024 Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate Achievement Nov. 1, 2023 Production of "Epitope region-bridging biparatopic antibody" -Improving the functionality of TNFR2 antagonist through 1:1 binding design- Achievement Jun. 28, 2023 Elucidation of the Mode of Action of Novel Universal Influenza Vaccine Candidates Achievement Feb. 28, 2023 Anti-IL-8 antibody, Improves Inflammation and Fibrosis in Endometriosis in an Industry-Government-Academia Non-Clinical Study Published in Science Translational Medicine Achievement Nov. 28, 2022 D-Amino acids: Signaling severity in viral infection Achievement Mar. 22, 2022 NIBIOHN Identifies Tissue-specific Exosome Marker Candidates from Blood Achievement Feb. 17, 2022 Host Immune-dependent Novel Anti-coronavirus Antibody - Potential Candidate as Broad-spectrum Therapeutic Agent for Coronavirus Diseases Caused by Different Coronaviruses, including Variants Achievement Dec. 7, 2021 D-Serine is useful for the rapid and precise measurement of kidney function News Oct. 19, 2020 Dr Tomonori Kimura, Director of Center for Rare Disease Research, received the Catalyst Award for Healthy Longevity from National Academy of Medicine. News Apr. 24, 2020 Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine News Mar. 26, 2019 Identification of D-serine as a dual biomarker for the estimation of kidney function and for the early diagnosis of kidney diseases News Apr. 1, 2015 The National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN) was formed in April 2015 by combining the National Institute of Biomedical Innovation (NIBIO) and the National Institute of Health and Nutrition (NIHN).